Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Reggio Emilia
Clinical trial register · Italy

Clinical Trials in Reggio Emilia, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Italy and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 6778 matching records held by the registry are in this view. Synced 08 Oct 2026, 03:19 UTC
6778
Studies in scope
all four open statuses
4069
Recruiting now
open to new participants
1018
Lead sponsors
across recruiting studies
Top sites
Milan 2843 Bologna 1305 Roma 1274 Naples 984 Rome 967
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Azienda USL Reggio Emilia - IRCCS32 AstraZeneca8 Novartis Pharmaceuticals6 IRCCS Azienda Ospedaliero-Universitaria di Bologna5 Amgen4
Site location
Milan2843 Bologna1305 Roma1274 Naples984 Rome967
All 489 locations
Target enrolment
to

Trials with a site in Reggio Emilia

139 of 6778 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Italy
Start
Not yet open
Azienda USL Reggio Emilia - IRCCS
Not applicable
160
Reggio Emilia
2027-12
Not yet open
Azienda USL Reggio Emilia - IRCCS
Observational
210
Bari, Bologna, Ferrara, Meldola, Milan, Modena, Naples, Reggio Emilia
2026-08-30
Not yet open
University Medical Center Groningen
Not applicable
292
Florence, Lavagna, Milan, Nola, Reggio Emilia, Roma, Tricase
2026-07
Recruiting
Ono Pharmaceutical Co., Ltd.
Phase 3
132
Brescia, Meldola, Reggio Emilia
2026-06-12
Recruiting
HematoCare: Feasibility of a Survivorship Care Plan for Hematologic Cancer Patients Undergoing HSCT
NCT07579065Hematologic Neoplasm, Hematopoietic Stem Cell Transplantation, Survivorship, Cancer Survivorship
Azienda USL Reggio Emilia - IRCCS
Not applicable
40
Reggio Emilia
2026-06
Recruiting
Novo Nordisk A/S
Phase 3
5,610
Chieti, Cosenza, Naples, Bentivoglio, Bologna, Ferrara, Reggio Emilia, Udine
2026-05-11
Recruiting
Istituto Ortopedico Rizzoli
Observational
943
Bologna, Reggio Emilia
2026-03-09
Recruiting
Philogen S.p.A.
Phase 1
42
Reggio Emilia, Verona
2026-03-04
Recruiting
Poland-Italy Aortic Research Bridge Real World Registry
NCT07476196Abdominal Aortic Aneurysm
American Heart of Poland
Observational
200
Castel Volturno, Catania, Pozzilli, Reggio Emilia, San Donato Milanese
2026-03-01
Recruiting
Janssen Research & Development, LLC
Phase 3
400
Alessandria, Brescia, Milan, Pisa, Reggio Emilia, Roma, Rozzano, San Giovanni Rotondo
2026-02-04
Active, closed
Low Dose Radiotherapy in Primary Indolent Cutaneous B-cell Lymphoma
NCT07310745Primary Indolent Cutaneous B-cell Lymphoma
Azienda USL Reggio Emilia - IRCCS
Observational
52
Reggio Emilia
2025-12-18
Recruiting
Hoffmann-La Roche
Phase 2
160
Reggio Emilia, Rome, Rozzano
2025-12-05
Recruiting
Genmab
Phase 3
660
Bologna, Meldola, Monza, Milan, Prato, Reggio Emilia
2025-11-28
Recruiting
Sanofi
Observational
1,000
Ancona, Novara, Reggio Emilia, Roma
2025-11-17
Active, closed
Targeting Immunosuppressive Treatment for Non-infectious Uveitis Using Aqueous Humor Cytokine Profiles
NCT07262437Uveitis Posterior Non-Infectious, Inflammation Eye, Uveitis, Uveitis, Anterior
University of Milan
Not applicable
220
Milan, Reggio Emilia
2025-11-15
Recruiting
AbbVie
Phase 3
561
Cona, Florence, Rome, Ancona, Reggio Emilia
2025-11-05
Recruiting
Sanofi
Phase 3
942
Milan, Rozzano, Padova, Pavia, Reggio Emilia, Tradate (Va)
2025-09-16
Recruiting
Azienda USL Reggio Emilia - IRCCS
Observational
50
Reggio Emilia
2025-09-01
Recruiting
A Potential Relationship Between Treatment With Tyrosine Kinase Inhibitors and Erectile Dysfunction in Male Patients With Chronic Myeloid Leukemia
NCT07061145Chronic Myelocytic Leukemia, Erectile Dysfunctions, CVD - Cardiovascular Disease, Tyrosine Kinase Inhibitor
Azienda USL Reggio Emilia - IRCCS
Observational
350
Reggio Emilia
2025-07-01
Recruiting
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
NCT06966700Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
DrugsEpirubicin·Adriamycin·Xeloda·Sacituzumab tirumotecan
Merck Sharp & Dohme LLC
Phase 3
2,400
Monza, Livorno, Ancona, Bergamo, Genova, Milan, Pisa, Reggio Emilia
2025-06-30
Recruiting
The Implementation of the Go Wish Game to Promote Advance Care Planning in Onco- Hematologic Disease
NCT06795815Leukemia, Multiple Mieloma, Advanced Solid Tumors, Lymphoma
Azienda USL Reggio Emilia - IRCCS
Not applicable
75
Reggio Emilia
2025-06-30
Recruiting
Ipsen
Phase 2
132
Bologna, Milan, Pavia, Reggio Emilia
2025-06-30
Recruiting
Centralization and Oncologic Outcomes in Ovarian Cancer
NCT07075939Epithelial Ovarian Cancer, Ovarian Neoplasms, Advanced Ovarian Cancer
Azienda USL Reggio Emilia - IRCCS
Observational
200
Carpi, Mirandola, Pavullo nel Frignano, Sassuolo, Vignola, Reggio Emilia, Modena
2025-06-27
Recruiting
Azienda USL Reggio Emilia - IRCCS
Observational
190
Reggio Emilia
2025-06-17
Recruiting
SLIT ABS: Study on Patients With Autoimmune Podocytopathy
NCT07516964Nephrotic Syndrome With Edema (Diagnosis), Minimal Change Nephrotic Syndrome, Focal Segmental Glomerulosclerosis (FSGS), Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy
Meyer Children's Hospital IRCCS
Not applicable
50
Bagno a Ripoli, Florence, Bologna, Genova, Parma, Pisa, Prato, Reggio Emilia
2025-06-10
Active, closed
Swedish Orphan Biovitrum
Phase 2
156
Milan, Padova, Reggio Emilia, Roma
2025-05-28
Recruiting
Azienda USL Reggio Emilia - IRCCS
Phase 2
56
Reggio Emilia
2025-05-26
Recruiting
Pfizer
Phase 2
252
Monserrato, Reggio Emilia, Rozzano, Orbassano, Salerno, Torino, Siena
2025-05-20
Recruiting
Merck Sharp & Dohme LLC
Phase 2
594
Meldola, Rozzano, Palermo, Alessandria, Milan, Naples, Reggio Emilia
2025-04-11
Recruiting
Azienda USL Reggio Emilia - IRCCS
Observational
30
Reggio Emilia
2025-04-01
Not yet open
IRCCS Burlo Garofolo
Observational
100
Reggio Emilia, Trieste, Udine
2025-04-01
Recruiting
AstraZeneca
Phase 3
600
Catania, Florence, Milan, Monza, Naples, Reggio Emilia, Roma, Rome
2025-03-27
Active, closed
Immutep S.A.S.
Phase 3
756
Avellino, Aviano, Candiolo, Milan, Naples, Perugia, Reggio Emilia, Terni
2025-03-21
Recruiting
Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical Evolution
NCT07214324Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM), Multiple Myeloma (MM)
Azienda USL Reggio Emilia - IRCCS
Observational
60
Bologna, Catania, Palermo, Reggio Emilia
2025-03-17
Recruiting
Amgen
Phase 3
844
Udine, Rome, Milan, Turin, Verona, Pisa, Reggio Emilia
2025-02-25
Recruiting
Bayer
Phase 2
111
Milan, Reggio Emilia, Roma
2025-02-13
Recruiting
Azienda USL Reggio Emilia - IRCCS
Not applicable
2,200
Reggio Emilia
2025-02-01
Active, closed
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
NCT06710132Solid Tumors, Gastric Cancer, Non-Small Cell Lung Cancer (NSCLC), Pancreatic Cancer
DrugM9140
EMD Serono Research & Development Institute, Inc.
Phase 1/2
184
Rome, Ancona, Milan, Naples, Padova, Pisa, Reggio Emilia, Roma
2025-01-29
Recruiting
Radiologic Features of Rheumatoid Arthritis Interstitial Lung Disease at Chest High Resolution Computed Tomography
NCT07174102Reumatoid Arthritis, Interstitial Lung Disease Due to Systemic Disease (Disorder), Idiopathic Pulmonary Fibrosis (IPF), Connective Tissue Disease (CTD)
Azienda Unita Sanitaria Locale di Piacenza
Observational
500
Ferrara, Modena, Piacenza, Reggio Emilia
2025-01-08
Recruiting
Azienda USL Reggio Emilia - IRCCS
Observational
40
Modena, Padova, Reggio Emilia, Roma
2024-11-02
Recruiting
argenx
Phase 3
69
Bassano del Grappa, Florence, Milan, Novara, Ravenna, Reggio Emilia, Torino, Trieste
2024-10-18
Recruiting
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
NCT06562192Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, HR+/HER2- Ductal and Lobular Breast Cancer, Triple Negative Breast Cancer
Novartis Pharmaceuticals
Phase 1
162
Milan, Reggio Emilia
2024-10-15
Recruiting
North Eastern German Society of Gynaecological Oncology
Phase 2
640
Bologna, Brescia, Lecco, Milan, Monserrato, Padova, Pisa, Reggio Emilia
2024-10-11
Active, closed
A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis
NCT06431373Uveitis, Posterior, Uveitis, Intermediate, Uveitis
Priovant Therapeutics, Inc.
Phase 3
371
Perugia, Milan, Reggio Emilia, Roma
2024-09-11
Recruiting
Study of Axial and Cognitive Symptoms and Biomarkers of Neurodegeneration in Brain-first and Body-first PD
NCT07187843Parkinson Disease, Parkinsonian Disorders, Brain Disease, Basal Ganglia Diseases
Azienda USL Reggio Emilia - IRCCS
Observational
150
Reggio Emilia
2024-09-04
Recruiting
Multidimensional Omics Analysis in Malignant Pleural Mesothelioma
NCT07561190Malignant Pleural Mesothelioma (MPM)
Azienda USL Reggio Emilia - IRCCS
Observational
300
Catania, Naples, Reggio Emilia, Roma
2024-08-30
Recruiting
Multicenter Retrospective Observational Study of Relapsed Diffuse Large B-Cell Lymphoma Presenting as Indolent Lymphoma
NCT06822829Diffuse Large B Cell Lymphoma (DLBCL), Indolent B-Cell Lymphomas, Indolent B Cell Lymphoma
Azienda USL Reggio Emilia - IRCCS
Observational
50
Reggio Emilia
2024-08-19
Recruiting
AstraZeneca
Phase 3
788
Bergamo, Bologna, Milan, Modena, Naples, Padova, Reggio Emilia, Rome
2024-08-01
Active, closed
Astellas Pharma Global Development, Inc.
Phase 3
982
Bologna, Genova, Milan, Mirano, Pavia, Reggio Emilia, Terni
2024-07-31
Active, closed
AstraZeneca
Phase 3
339
Brescia, Cona, Florence, Milan, Naples, Reggio Emilia, Roma, Rome
2024-06-29
Recruiting
Clinical Management and Outcomes of Primary Ovarian Leiomyosarcoma
NCT06749600Primary Ovarian Leiomyosarcoma
Azienda USL Reggio Emilia - IRCCS
Observational
30
Modena, Parma, Reggio Emilia, Avellino, Catania, Milan, Monza, Naples
2024-06-14
Active, closed
GlaxoSmithKline
Phase 4
303
Brescia, Ferrara, Milan, Pisa, Reggio Emilia, Rome, Rozzano
2024-06-06
Active, closed
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
NCT06328738HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors, HER2 Amplification
DrugsELVN-002·Eribulin·Leucovorin·Trastuzumab
Enliven Therapeutics
Phase 1
275
Catanzaro, Milan, Monza, Pisa, Reggio Emilia, Rome
2024-05-30
Active, closed
Novartis Pharmaceuticals
Phase 1
42
Reggio Emilia
2024-05-15
Active, closed
Amgen
Phase 3
434
Reggio Emilia, Udine, Rome, Milan, Novara, Florence, Verona, Catania
2024-04-08
Recruiting
Italfarmaco
Phase 3
220
Bari, Reggio Calabria, Bologna, Meldola, Reggio Emilia, Udine, Rome, Bergamo
2024-03-26
Active, closed
Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)
NCT06117774Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
DrugTarlatamab
Amgen
Phase 3
404
Aviano PN, Milan, Orbassano, Padova, Perugia, Pisa, Reggio Emilia, Rozzano MI
2024-02-20
Active, closed
Genmab
Phase 3
1,095
Rozzano, Candiolo, Bologna, Catania, Palermo, Reggio Emilia, Roma
2024-02-05
Recruiting
Azienda USL Reggio Emilia - IRCCS
Observational
4,500
Bologna, Modena, Reggio Emilia
2024-02-01
Recruiting
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 2
66
Reggio Emilia
2024-01-16
Recruiting
Insel Gruppe AG, University Hospital Bern
Observational
2,800
Naples, Palermo, Perugia, Reggio Emilia
2024-01-01
Recruiting
Azienda USL Reggio Emilia - IRCCS
Observational
3,000
Brindisi, Milan, Reggio Emilia, Trento
2023-11-23
Recruiting
AstraZeneca
Phase 3
625
Bergamo, Empoli, Milan, Modena, Naples, Padova, Reggio Emilia, Roma
2023-11-23
Active, closed
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Exemestane·Anastrozole·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
510
Avellino, Bologna, Meldola, Modena, Reggio Emilia, Udine, Rome, Milan
2023-11-16
Recruiting
Grupo Espanol de Tumores Neuroendocrinos
Phase 3
170
Reggio Emilia, Bari, Meldola, Milan, Roma, Verona
2023-10-27
Recruiting
Merck Sharp & Dohme LLC
Phase 3
735
Alessandria, Milan, Reggio Emilia
2023-08-08
Recruiting
GlaxoSmithKline
Phase 3
892
Cagliari, Genova, Milan, Naples, Padova, Pisa, Reggio Emilia, Roma
2023-08-01
Recruiting
Diagnosis and Outcomes of Placental Accretism
NCT06833606Placenta Accreta
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Observational
70
Bologna, Cesena, Forlì, Modena, Parma, Reggio Emilia, Rimini
2023-07-17
Recruiting
Population Health Research Institute
Not applicable
5,100
Arezzo, Bologna, Ferrara, Grosseto, Reggio Emilia, Rome
2023-06-22
Active, closed
Servier Affaires Médicales
Phase 3
299
Bologna, Florence, Milan, Naples, Reggio Emilia, Roma, Rozzano, San Giovanni Rotondo
2023-05-03
Recruiting
The Unmet Needs of Cancer Survivors in Ausl IRCCS Reggio Emilia
NCT06236373Cancer, Breast Cancer, Prostate Cancer, Thyroid Cancer
University of Modena and Reggio Emilia
Observational
45
Reggio Emilia
2023-04-20
Active, closed
Bayer
Phase 3
985
Foggia, Naples, Bologna, Modena, Reggio Emilia, Aviano, Rome, Genoa
2023-04-03
Active, closed
Janssen Research & Development, LLC
Phase 3
614
Bologna, Milan, Palermo, Pisa, Reggio Emilia, Roma, Siena, Turin
2023-03-29
Active, closed
Azienda USL Reggio Emilia - IRCCS
Not applicable
31
Reggio Emilia
2023-03-10
Active, closed
AstraZeneca
Phase 2
188
Avellino, Brescia, Lecce, Milan, Naples, Palermo, Peschiera del Garda, Reggio Emilia
2023-03-06
Recruiting
Universita di Verona
Not applicable
1,030
Cuneo, Reggio Emilia, Verona
2023-01-16
Recruiting
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase 2
37
Novara, Bergamo, Milan, Naples, Padova, Reggio Emilia
2022-12-15
Active, closed
Almirall, S.A.
Phase 4
447
Arezzo, Brescia, Genova, Modena, Naples, Reggio Emilia, Roma, Rozzano
2022-10-24
Active, closed
Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies
NCT05397496B-cell Non-Hodgkin Lymphoma (B-NHL), B-cell Acute Lymphoblastic Leukemia (B-ALL)
DrugPIT565
Novartis Pharmaceuticals
Phase 1
61
Reggio Emilia
2022-10-03
Recruiting
Istituto Auxologico Italiano
Observational
3,000
Mascalucia, Bari, Milan, Reggio Emilia, Trieste
2022-10-01
Active, closed
Kite, A Gilead Company
Phase 3
231
Bergamo, Bologna, Milan, Reggio Emilia, Rozzano
2022-09-22
Recruiting
Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer
NCT05254171Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV
DrugsAbraxane·Nab-paclitaxel·Gemcitabine
Panbela Therapeutics, Inc.
Phase 2/3
600
San Giovanni Rotondo, Meldola, Reggio Emilia, Milan, Candiolo, Pisa, Terni, Verona
2022-08-08
Recruiting
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05254743Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
DrugsPirtobrutinib·Ibrutinib
Loxo Oncology, Inc.
Phase 3
737
Alessandria, Bologna, Meldola, Milan, Reggio Emilia
2022-07-22
Active, closed
Hoffmann-La Roche
Phase 3
922
Naples, Reggio Emilia, Rimini, Rome, Brescia, Milan, Rozzano, Misterbianco (CT)
2022-07-18
Active, closed
First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours
NCT05495295Malignant Tumor, Advanced Solid Tumor, Glioblastoma Multiforme, Metastatic Cancer
Phost'In Therapeutics
Phase 1
149
Milan, Reggio Emilia
2022-07-18
Active, closed
Azienda USL Reggio Emilia - IRCCS
Not applicable
16
Reggio Emilia
2022-07-07
Recruiting
Changing Paragidms In The Prognostic Assessment Of Hodgkin Lymphoma
NCT06822855Classical Hodgkin Lymphoma, Classical Hodgkin Lymphoma Recurrent, Classical Hodgkin Lymphoma Refractory
Azienda USL Reggio Emilia - IRCCS
Observational
755
Milan, Reggio Emilia, Avellino, Brescia, Padova, Palermo, Perugia, Piacenza
2022-06-23
Recruiting
CardioPulmonary Resuscitation With Argon (CPAr) Trial
NCT05482945Cardiac Arrest, Out-Of-Hospital, Cardiac Arrest With Successful Resuscitation
Mario Negri Institute for Pharmacological Research
Phase 2
120
Genova, Monza, Milan, Parma, Pordenone, Reggio Emilia, Roma, Trento
2022-05-30
Active, closed
Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 2
154
Turin, Florence, Genova, Milan, Pavia, Reggio Emilia, Roma
2022-03-29
Active, closed
BeOne Medicines
Phase 3
799
Aviano, Bologna, Florence, Milan, Novara, Padova, Pavia, Reggio Emilia
2022-03-10
Recruiting
Azienda Ospedaliero-Universitaria di Parma
Not applicable
100
Meldola, Bologna, Ferrara, Parma, Piacenza, Ravenna, Reggio Emilia, Rimini
2022-03-01
Active, closed
Unraveling the Role of Extracellular Vesicles-driven Senescence in Myeloproliferative Neoplasms
NCT06798805Essential Thrombocythemia (ET), Myelofibrosis (MF), Polycythemia Vera (PV)
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Observational
110
Bologna, Brescia, Meldola, Ravenna, Reggio Emilia
2022-02-15
Recruiting
Takeda
Phase 2
135
Bari, Bologna, Brescia, Florence, Genova, Milan, Reggio Emilia, Roma
2021-12-16
Active, closed
Jazz Pharmaceuticals
Phase 3
920
Bologna, Candiolo, Genova, Meldola, Milan, Modena, Reggio Emilia, Rome
2021-12-02
Recruiting
Azienda USL Reggio Emilia - IRCCS
Not applicable
282
Bologna, Genova, Milan, Modena, Reggio Emilia
2021-11-18
Recruiting
Azienda USL Reggio Emilia - IRCCS
Observational
180
Reggio Emilia
2021-11-17
Active, closed
International Extranodal Lymphoma Study Group (IELSG)
Phase 2
26
Brescia, Milan, Novara, Ravenna, Reggio Emilia, Varese
2021-10-20
Active, closed
A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP
NCT04971226Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
DrugsBosutinib·Asciminib·ABL001·Nilotinib
Novartis Pharmaceuticals
Phase 3
405
Bologna, Milan, Reggio Emilia, Roma, Verona
2021-10-06
Recruiting
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT05059444Bladder Carcinoma, Ureter Carcinoma, Renal Pelvis Carcinoma, Non-small Cell Lung Cancer
Guardant Health, Inc.
Observational
2,285
Meldola, Reggio Emilia, Roma
2021-09-07
Active, closed
Janssen Research & Development, LLC
Phase 4
411
Ancona, Monserrato, Reggio Emilia, Roma, Rozzano (MI), Verona
2021-08-30
Active, closed
Hoffmann-La Roche
Phase 3
4,170
Avellino, Naples, Bologna, Meldola, Reggio Emilia, Roma, Milan, Rozzano (MI)
2021-08-27
Active, closed
AstraZeneca
Phase 3
712
Bari, Florence, Meldola, Milan, Padova, Pozzuoli, Reggio Emilia, Roma
2021-08-05
Recruiting
Novartis Pharmaceuticals
Phase 1/2
222
Meldola, Milan, Naples, Reggio Emilia
2021-07-30
Recruiting
New AI-based Technologies in Nuclear Medicine
NCT07174089Patients Undergoing PET/CT Investigation or Nuclear Medicine Therapy
Azienda USL Reggio Emilia - IRCCS
Observational
1,500
Reggio Emilia
2021-07-30
Active, closed
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Observational
100
Bologna, San Giovanni Rotondo, Bari, Cagliari, Novara, Palermo, Reggio Emilia, Terni
2021-05-20
Active, closed
Azienda USL Reggio Emilia - IRCCS
Observational
700
Reggio Emilia, Bologna, Ferrara, Forlì, Modena, Parma, Rimini
2021-05-10
Active, closed
Azienda USL Reggio Emilia - IRCCS
Phase 3
280
Coppito, Guastalla, Reggio Emilia, Mirano
2021-04-30
Recruiting
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
NCT04728893Hematologic Malignancies, Waldenstroms Macroglobulinaemia, Non-Hodgkins Lymphoma, Chronic Lymphocytic Leukaemia
DrugNemtabrutinib
Merck Sharp & Dohme LLC
Phase 2
490
Bari, Bologna, Brescia, Milan, Naples, Pavia, Reggio Emilia, Roma
2021-04-05
Recruiting
Endoscopic Resection of Gastrointestinal Neoplasms
NCT04780256Endoscopic Mucosal Resection, Endoscopic Submucosal Dissection, Gastric Neoplasm, Colonic Neoplasms
Azienda USL Reggio Emilia - IRCCS
Observational
2,000
Reggio Emilia
2021-03-15
Recruiting
Secukinumab Open Label Roll-over Extension Protocol
NCT04638647Autoimmunity, Inflammation
DrugSecukinumab
Novartis Pharmaceuticals
Phase 4
1,000
Florence, Reggio Emilia
2020-12-22
Active, closed
Amgen
Phase 3
135
Florence, Milan, Pisa, Reggio Emilia, Torino, Verona
2020-12-04
Active, closed
Genmab
Phase 1/2
543
Bergamo, Bologna, Candiolo, Meldola, Milan, Pavia, Reggio Emilia
2020-11-03
Recruiting
IFOM ETS - The AIRC Institute of Molecular Oncology
Observational
1,500
Bergamo, Milan, Novara, Padova, Pavia, Roma, Reggio Emilia
2020-07-16
Recruiting
Peripheral Extreme Revascularization in "No-option" Patiens With Chronic Limb Threatening Ischemia
NCT06277362Peripheral Arterial Disease, Critical Limb-Threatening Ischemia, Diabetic Foot
EndoCore Lab s.r.l.
Observational
50
Ancona, Belluno, Cesena, Conegliano, Naples, Reggio Emilia, Trento, Perugia
2020-01-31
Active, closed
Advanced Accelerator Applications
Phase 3
226
Bologna, Genova, Meldola, Milan, Naples, Reggio Emilia, Roma
2020-01-08
Active, closed
Pfizer
Phase 3
1,068
Misterobianco (CT), Cremona, Rozzano, Turin, Reggio Emilia, Arezzo, Bari, Genova
2019-12-30
Active, closed
Regeneron Pharmaceuticals
Phase 2
515
Milan, Bologna, Livorno, Novara, Perugia, Ravenna, Reggio Emilia, Varese
2019-11-13
Active, closed
Celgene
Phase 1/2
424
Brescia, Milan, Reggio Emilia, Torino
2019-09-30
Recruiting
Centro di Riferimento Oncologico - Aviano
Observational
78
Aviano, Genova, Messina, Milan, Modena, Naples, Reggio Emilia, Roma
2019-08-27
Active, closed
My Personalized Breast Screening
NCT03672331Breast Screening
UNICANCER
Not applicable
53,142
Reggio Emilia
2019-07-18
Active, closed
Consorzio Futuro in Ricerca
Not applicable
1,445
Bologna, Ferrara, Cotignola, Ravenna, Reggio Emilia, Rimini, Agrigento, Caserta
2019-07-15
Active, closed
Dizal Pharmaceuticals
Phase 1/2
315
Aviano, Catania, Florence, Meldola, Milan, Parma, Ravenna, Reggio Emilia
2019-07-09
Active, closed
Biomarkers of Cancer-Associated Myositis
NCT06808672Dermatomyositis
Azienda USL Reggio Emilia - IRCCS
Observational
50
Bari, Reggio Emilia
2019-06-13
Active, closed
Bioimpedance Analysis in Perioperative Assessment in Thoracic Surgery
NCT06796816Lung Resection, Adenocarcinoma of Lung
Azienda USL Reggio Emilia - IRCCS
Not applicable
1,000
Reggio Emilia
2019-04-01
Active, closed
Institut de Recherches Internationales Servier
Phase 3
856
Cagliari, Cremona, Naples, Padova, Pisa, Potenza, Reggio Emilia, Roma
2019-03-21
Active, closed
Azienda USL Reggio Emilia - IRCCS
Not applicable
10,156
Reggio Emilia, Milan, Verona
2019-03-01
Active, closed
AstraZeneca
Phase 3
1,407
Brescia, Lecce, Lecco, Milan, Mirano, Naples, Reggio Calabria, Reggio Emilia
2019-01-04
Active, closed
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
NCT03589326Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
DrugsPonatinib·Imatinib·Cytarabine·Vincristine
Takeda
Phase 3
245
Meldola, Genoa, Monza, Reggio Emilia, Mestre, Bologna, Lecce, Milan
2018-10-04
Active, closed
Janssen Research & Development, LLC
Phase 3
120
Ancona, Bologna, Cagliari, Padova, Reggio Emilia
2018-07-11
Active, closed
Oncology Institute of Southern Switzerland
Observational
370
Reggio Emilia, Novara
2018-03-01
Active, closed
Acerta Pharma BV
Phase 3
635
Bologna, Milan, Palermo, Parma, Pavia, Reggio Emilia, Rozzano, Turin
2017-04-05
Recruiting
Turning Point Therapeutics, Inc.
Phase 1/2
500
Milan, Palermo, Pordenone, Ravenna, Reggio Emilia, Roma, Terni
2017-03-07
Active, closed
Celgene
Phase 1/2
466
Meldola, Pavia, Reggio Emilia, Rome, Torino
2016-10-14
Recruiting
UMC Utrecht
Phase 3
20,000
Brescia, Milan, Palermo, Reggio Emilia, Rimini
2016-04-11
Recruiting
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Observational
1,000
Bologna, Reggio Emilia
2016-01-02
Active, closed
Hoffmann-La Roche
Phase 3
154
Bari, Bologna, Meldola, Reggio Emilia, Milan, Monza, Pisa
2015-02-02
Active, closed
IRCCS Azienda Ospedaliero-Universitaria di Bologna
Not applicable
1,507
Brixen, Merano, Mirano, Bologna, Bolzano, Ferrara, Reggio Emilia
2014-09
Active, closed
Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Etiology, Triggers, and Outcome
NCT01934725Brain Infarction, Ischemic Stroke, Thrombosis, Foramen Ovale, Patent
SECRETO Study Consortium
Observational
1,200
Brescia, Reggio Emilia
2013-11
Active, closed
AstraZeneca
Phase 3
736
Aviano, Bergamo, Carpi, Genova, Prato, Reggio Emilia, Varese
2005-02-13
Rows per page Showing 1–139 of 139
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Italian investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 10 October 2026. https://priyalifescience.com/clinical-trials-italy/city/reggio-emilia

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Italy and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 6,778 studies in total at the last sync on 08 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 139 of those studies with a site in Reggio Emilia.

How many clinical trials are recruiting in Reggio Emilia?

74 of the 139 studies on this page are recruiting new participants as of the 08 Oct 2026, 03:19 UTC sync. A further 4 have not yet opened recruitment, 61 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Reggio Emilia), 139 studies
PhaseStudiesRecruitingShare
Phase 3471833.8%
Observational393028.1%
Not applicable18812.9%
Phase 2171212.2%
Phase 1/2725%
Phase 1624.3%
Phase 4412.9%
Phase 2/3110.7%

Most active sponsors

Lead sponsors with the most studies (Reggio Emilia)
Lead sponsorStudiesRecruiting
Azienda USL Reggio Emilia - IRCCS3222
AstraZeneca83
Novartis Pharmaceuticals63
IRCCS Azienda Ospedaliero-Universitaria di Bologna52
Amgen41
Hoffmann-La Roche41
Janssen Research & Development, LLC41
Merck Sharp & Dohme LLC44
Genmab31
Bayer21
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.